Reference Detail

Ref Type
PMID
Authors C. Massard, A. Azaro, J.C. Soria, U. Lassen, C. Le Tourneau, C. Smith, U. Ohnmacht, G. Oakley, B.K.R. Patel, E.S.M. Yuen, K.A. Benhadji, J. Rodon
Title First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
Journal European Journal of Cancer
Vol
Issue
Date
URL http://www.sciencedirect.com/science/article/pii/S0959804916326326?via%3Dihub
Abstract Text European Journal of Cancer , Volume 69 , S15 http://www.sciencedirect.com/science/article/pii/S0959804916326326?via%3Dihub

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Therapy Description
Drug Name Trade Name Synonyms Drug Classes Drug Description
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown adenocarcinoma not applicable LY3039478 Phase I Actionable In a Phase I trial, a patient with adenoid cystic carcinoma demonstrated a metabolic response when treated with LY3039478 (European Journal of Cancer, Volume 69, S15). detail...
Unknown unknown testicular cancer not applicable LY3039478 Phase I Actionable In a Phase I trial, a patient with testicular cancer demonstrated a metabolic response when treated with LY3039478 (European Journal of Cancer, Volume 69, S15). detail...
Unknown unknown leiomyosarcoma not applicable LY3039478 Phase I Actionable In a Phase I trial, treatment with LY3039478 resulted in tumor necrosis in a patient with leiomyosarcoma (European Journal of Cancer, Volume 69, S15). detail...
Unknown unknown Advanced Solid Tumor not applicable LY3039478 Phase I Actionable In a Phase I trial, LY3039478 treatment resulted in 80% inhibition of plasma A-beta and more than 50% inhibition of Notch1-regulated genes in patients with advanced solid tumor, leading to partial response in 0.9% (1/110) and stable disease in 32.7% (36/110) of the patients (PMID: 30060061; NCT01695005). 30060061 detail...
Unknown unknown Advanced Solid Tumor not applicable LY3039478 Phase I Actionable In a Phase I trial, treatment with LY3039478 was well-tolerated and demonstrated some preliminary efficacy in patients with advanced solid tumors (J Clin Oncol 33, 2015 (suppl; abstr 2533)). detail...